REDMOND, Wash., & NIVELLES, Belgium – May 15, 2025 — Inventprise Inc., a clinical-stage vaccine invention company, announced today its selection of Quantoom Biosciences’ Ntensify midi system as the core technology to support its mRNA vaccine platform. mRNA technology is crucial for its rapid development capabilities, adaptability, and potential in responding to infectious diseases.

Quantoom’s Ntensify midi system is designed to enable the production of high-yield, low-contaminant mRNA with unparalleled quality. The system provides a GMP-grade, scalable, and automated solution, from phase I to commercial, making it ideal for vaccine developers like Inventprise. Integrating Quantoom’s technology with Inventprise’s vaccine development expertise enhances the potential for delivering affordable mRNA vaccines to underserved populations.

As a proof of concept, Inventprise is developing an RSV vaccine using Quantoom’s Ntensify solution to optimize the end-to-end process. The project is supported with funding from the Gates Foundation. The company also plans to apply the technology beyond RSV, ensuring rapid, scalable vaccine production in response to emerging infectious diseases. This strengthens Inventprise’s role in pandemic preparedness.

Leadership Perspectives

“The Quantoom midi system allows us to produce high-quality GMP mRNA vaccines quickly, addressing infectious disease challenges in our pursuit of improving global health,” said Yves Leurquin, president and CEO of Inventprise.

“We are honored that Inventprise has chosen our Ntensify technology to advance their RSV mRNA vaccine program,” said José Castillo, CEO of Quantoom Biosciences. “This milestone represents a major step in evolving mRNA vaccines beyond COVID-19 to protect vulnerable populations. Our collaboration reinforces our commitment to making high-quality, scalable mRNA production accessible to vaccine developers worldwide.”

About Inventprise

Inventprise is a clinical-stage vaccine invention company based in Redmond, Washington, with a presence in Europe. Founded in 2012 by Dr. Subhash Kapre, the company develops high-valency vaccines to protect against global infectious diseases. Leveraging advanced R&D, state-of-the-art manufacturing, and proprietary PEG Linker technology, Inventprise’s pipeline includes IVT PCV- 25, its lead 25-valent pneumococcal conjugate vaccine, and candidates targeting Group B Streptococcus, Shigella, and RSV. The company aims to deliver widely available, effective vaccines globally, including to low- and middle-income countries. Learn more at www.inventprise.com.